Fudan-Zhangjiang(SH:688505)2022-11-17 14:28Group 1: Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 and is primarily engaged in innovative research, development, manufacturing, and marketing in the biopharmaceutical sector [2]. - The company aims to be an innovator and leader in the biopharmaceutical industry, focusing on exploring clinical treatment gaps and providing more effective therapeutic solutions [2]. Group 2: Research and Development Platforms - The company has established multiple research platforms, including gene engineering, photodynamic technology, nanotechnology, and oral solid preparation technology [4]. - The research pipeline includes various indications, with a focus on antibody-drug conjugates (ADC) targeting cancers such as breast cancer and gastric cancer [5]. Group 3: Product Development and Clinical Trials - The main component of the drug Aira is aminolevulinic acid hydrochloride, with ongoing studies for indications including HPV-related cervical diseases and acne, with some projects already in Phase II clinical trials [3]. - The photodynamic therapy products Aira and Fumeida have shown significant clinical advantages over traditional laser treatments, including lower recurrence rates and better patient tolerance [4]. Group 4: Financial and Investment Insights - R&D investment has been increasing since the company's listing on the STAR Market, with R&D expenditure as a percentage of revenue rising from 12.68% in 2019 to 21.76% in 2021 [6]. - The company plans to maintain a high R&D investment ratio in the future, continuing to focus on advancing ongoing projects [6].